Moderna opens manufacturing and R&D facility in UK
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
BIL also holds an option to increase its equity stake by an additional 15%
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Zydus Pinkathon will be led by women to raise awareness on breast cancer and women's health
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Subscribe To Our Newsletter & Stay Updated